Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
14 juin 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
01 juin 2023 07h00 HE
|
Monopar Therapeutics Inc.
Patient in 520 mg/m2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m2 cohort achieved stable...
Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
11 mai 2023 07h00 HE
|
Monopar Therapeutics Inc.
Camsirubicin Phase 1b DoseEscalation Trial Enrolling 5th DoseLevel Cohort (650 mg/m2)MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study ResultsWILMETTE, Ill., May 11, 2023 (GLOBE...
Monopar to Present at the Jefferies Radiopharma Innovation Summit
28 mars 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
27 mars 2023 17h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., March 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
23 mars 2023 07h00 HE
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next WeekCamsirubicin Phase 1b Dose-Escalation Trial Now Enrolling 5th Dose-Level Cohort (650 mg/m2) WILMETTE, Ill.,...
Monopar to Present at the 35th Annual Roth Conference
07 mars 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials
27 févr. 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced...
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
14 févr. 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
26 janv. 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...